uniQure N.V.

QURE · NASDAQ

uniQure has a gene-therapy platform and clinical pipeline, but the latest filings show small revenue, large research spending, operating losses and a balance sheet that must fund trials through binary data and regulatory events.

Follow Add to Watchlist Ask Question

NASDAQ QURE Coverage Bootstrap uniQure N.V.

Latest ReportMay 20, 2026uniQure: the gene-therapy runway is still burning cashView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Admin-only preview

Valuation is limited to admins for now.

The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.